These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Steinpreis RE, Salamone JD. Brain Res; 1993 May 28; 612(1-2):263-70. PubMed ID: 8330204 [Abstract] [Full Text] [Related]
24. Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity. Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N. Psychopharmacology (Berl); 2018 May 28; 235(5):1593-1607. PubMed ID: 29637288 [Abstract] [Full Text] [Related]
25. Effects of the serotonin2A/2C receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex. Kuroki T, Kawahara T, Yonezawa Y, Tashiro N. Prog Neuropsychopharmacol Biol Psychiatry; 1999 Oct 28; 23(7):1259-75. PubMed ID: 10581647 [Abstract] [Full Text] [Related]
26. Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine. Fejgin K, Pålsson E, Wass C, Svensson L, Klamer D. Neuropsychopharmacology; 2008 Jul 28; 33(8):1874-83. PubMed ID: 17895915 [Abstract] [Full Text] [Related]
27. Effects of selective dopamine depletion in medial prefrontal cortex on basal and evoked extracellular dopamine in neostriatum. King D, Finlay JM. Brain Res; 1995 Jul 10; 685(1-2):117-28. PubMed ID: 7583236 [Abstract] [Full Text] [Related]
28. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L, Olsson E, Larsson K, Engberg G, Erhardt S. Int J Neuropsychopharmacol; 2009 May 10; 12(4):501-12. PubMed ID: 18796185 [Abstract] [Full Text] [Related]
29. On the mechanism of d-amphetamine-induced changes in glutamate, ascorbic acid and uric acid release in the striatum of freely moving rats. Miele M, Mura MA, Enrico P, Esposito G, Serra PA, Migheli R, Zangani D, Miele E, Desole MS. Br J Pharmacol; 2000 Feb 10; 129(3):582-8. PubMed ID: 10711358 [Abstract] [Full Text] [Related]
30. PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments. Castañé A, Santana N, Artigas F. Psychopharmacology (Berl); 2015 Nov 10; 232(21-22):4085-97. PubMed ID: 25943167 [Abstract] [Full Text] [Related]
31. Clozapine-induced dopamine release in the medial prefrontal cortex is augmented by a moderate concentration of locally administered tyrosine but attenuated by high tyrosine concentrations or by tyrosine depletion. Jaskiw GE, Kirkbride B, Newbould E, Young D, Durkalski V, Bongiovanni R. Psychopharmacology (Berl); 2005 Jun 10; 179(4):713-24. PubMed ID: 15682305 [Abstract] [Full Text] [Related]
32. Characterization of the phencyclidine-induced increase in prefrontal cortical dopamine metabolism in the rat. Umino A, Takahashi K, Nishikawa T. Br J Pharmacol; 1998 May 10; 124(2):377-85. PubMed ID: 9641556 [Abstract] [Full Text] [Related]
33. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Nishijima K, Kashiwa A, Hashimoto A, Iwama H, Umino A, Nishikawa T. Synapse; 1996 Apr 10; 22(4):304-12. PubMed ID: 8867025 [Abstract] [Full Text] [Related]
34. Different roles of group I and group II metabotropic glutamate receptors on phencyclidine-induced dopamine release in the rat prefrontal cortex. Maeda J, Suhara T, Okauchi T, Semba J. Neurosci Lett; 2003 Jan 23; 336(3):171-4. PubMed ID: 12505620 [Abstract] [Full Text] [Related]
35. Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis studies. Wan RQ, Giovanni A, Kafka SH, Corbett R. Behav Brain Res; 1996 Aug 23; 78(2):211-23. PubMed ID: 8864054 [Abstract] [Full Text] [Related]
36. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. Darracq L, Blanc G, Glowinski J, Tassin JP. J Neurosci; 1998 Apr 01; 18(7):2729-39. PubMed ID: 9502830 [Abstract] [Full Text] [Related]
37. Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat. Gruber SH, Nomikos GG, Mathé AA. Neuropsychopharmacology; 2002 May 01; 26(5):595-604. PubMed ID: 11927184 [Abstract] [Full Text] [Related]
38. Regulation of medial prefrontal cortex dopamine by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptors. Wu WR, Li N, Sorg BA. Neuroscience; 2002 May 01; 114(2):507-16. PubMed ID: 12204218 [Abstract] [Full Text] [Related]
39. [Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice]. Eremin KO, Saransaari P, Oja S, Raevskiĭ KS. Eksp Klin Farmakol; 2004 May 01; 67(2):8-11. PubMed ID: 15188751 [Abstract] [Full Text] [Related]
40. Reduction of dopamine release and synthesis by repeated amphetamine treatment: role in behavioral sensitization. Imperato A, Obinu MC, Carta G, Mascia MS, Casu MA, Gessa GL. Eur J Pharmacol; 1996 Dec 19; 317(2-3):231-7. PubMed ID: 8997605 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]